Hoth Therapeutics Inc (NASDAQ:HOTH) shares gapped up before the market opened on Tuesday . The stock had previously closed at $2.33, but opened at $2.53. Hoth Therapeutics shares last traded at $2.53, with a volume of 20 shares.

Separately, Zacks Investment Research downgraded Hoth Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 29th.

The firm has a 50 day moving average of $2.58 and a two-hundred day moving average of $3.00.

Hoth Therapeutics (NASDAQ:HOTH) last announced its earnings results on Thursday, August 13th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.06). As a group, equities analysts forecast that Hoth Therapeutics Inc will post -0.6 earnings per share for the current year.

A number of large investors have recently made changes to their positions in HOTH. Two Sigma Securities LLC bought a new stake in Hoth Therapeutics during the 2nd quarter valued at approximately $28,000. Game Plan Financial Advisors LLC bought a new stake in Hoth Therapeutics during the 2nd quarter valued at approximately $28,000. Magnus Financial Group LLC bought a new stake in Hoth Therapeutics during the 2nd quarter valued at approximately $34,000. Goldman Sachs Group Inc. bought a new stake in shares of Hoth Therapeutics in the 2nd quarter worth approximately $41,000. Finally, Wedbush Securities Inc. bought a new stake in shares of Hoth Therapeutics in the 2nd quarter worth approximately $59,000. Hedge funds and other institutional investors own 2.14% of the company’s stock.

Hoth Therapeutics Company Profile (NASDAQ:HOTH)

Hoth Therapeutics, Inc, a development stage biopharmaceutical company, focuses on developing targeted therapeutics for atopic dermatitis. It intends to use the BioLexa Platform to develop 2 topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures.

Featured Article: Compound Interest and Why It Matters When Investing

Receive News & Ratings for Hoth Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hoth Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.